Biopharmx Stock Price, News & Analysis (NYSEAMERICAN:BPMX)

$0.11 0.00 (0.00 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$0.11
Today's Range$0.11 - $0.11
52-Week Range$0.11 - $0.90
Volume2.54 million shs
Average Volume1.55 million shs
Market Capitalization$14.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32

About Biopharmx (NYSEAMERICAN:BPMX)

Biopharmx logoBioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.

Receive BPMX News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:BPMX
CUSIPN/A
Phone+1-650-8895020

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.34)
Net IncomeN/A
Net Margins-22,005.88%
Return on Equity-5,749.08%
Return on Assets-240.31%

Miscellaneous

EmployeesN/A
Outstanding Shares124,940,000

Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions

What is Biopharmx's stock symbol?

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) announced its earnings results on Wednesday, September, 13th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.06). The biotechnology company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Biopharmx had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%. View Biopharmx's Earnings History.

Where is Biopharmx's stock going? Where will Biopharmx's stock price be in 2017?

3 equities research analysts have issued 1-year target prices for Biopharmx's shares. Their predictions range from $1.50 to $3.00. On average, they anticipate Biopharmx's share price to reach $2.50 in the next year. View Analyst Ratings for Biopharmx.

Are investors shorting Biopharmx?

Biopharmx saw a decrease in short interest during the month of November. As of November 30th, there was short interest totalling 5,070,482 shares, a decrease of 0.7% from the November 15th total of 5,108,040 shares. Based on an average trading volume of 4,382,333 shares, the short-interest ratio is presently 1.2 days. Approximately 4.9% of the company's stock are short sold.

Who are some of Biopharmx's key competitors?

Who are Biopharmx's key executives?

Biopharmx's management team includes the folowing people:

  • James R. Pekarsky, Chairman of the Board, Chief Executive Officer (Age 55)
  • Anja B. Krammer, President, Director (Age 47)
  • Gregory David Kitchener, Chief Financial Officer, Executive Vice President - Finance
  • Kin F. Chan Ph.D., Executive Vice President - Research & Development (Age 41)
  • AnnaMarie Daniels, Executive Vice President - Clinical and Regulatory Affairs
  • Stephen Morlock, Independent Director (Age 61)
  • Ping Wang, Independent Director (Age 38)

How do I buy Biopharmx stock?

Shares of Biopharmx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biopharmx's stock price today?

One share of Biopharmx stock can currently be purchased for approximately $0.11.

How big of a company is Biopharmx?

Biopharmx has a market capitalization of $14.61 million.

How can I contact Biopharmx?

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.


MarketBeat Community Rating for Biopharmx (BPMX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biopharmx (NYSEAMERICAN:BPMX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.50$2.50$2.50$3.00
Price Target Upside: 2,172.73% upside777.19% upside733.33% upside506.18% upside

Biopharmx (NYSEAMERICAN:BPMX) Consensus Price Target History

Price Target History for Biopharmx (NYSEAMERICAN:BPMX)

Biopharmx (NYSEAMERICAN:BPMX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/8/2017Maxim GroupReiterated RatingBuy$1.50View Rating Details
9/19/2017HC WainwrightReiterated RatingBuy$3.00View Rating Details
6/3/2017Roth CapitalSet Price TargetBuy$3.00View Rating Details
(Data available from 12/16/2015 forward)

Earnings

Biopharmx (NYSEAMERICAN:BPMX) Earnings History and Estimates Chart

Earnings by Quarter for Biopharmx (NYSEAMERICAN:BPMX)

Biopharmx (NYSEAMERICAN BPMX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/13/2017Q2 2018($0.06)($0.06)$0.02 million$0.02 millionViewN/AView Earnings Details
6/13/2017Q1 2018($0.07)($0.07)$0.03 million$0.02 millionViewN/AView Earnings Details
12/13/2016Q3 2017($0.15)($0.13)ViewN/AView Earnings Details
6/14/2016Q117($0.17)($0.16)ViewListenView Earnings Details
4/26/2016Q416($0.17)($0.18)ViewListenView Earnings Details
12/14/2015Q316($0.19)($0.17)ViewN/AView Earnings Details
9/14/2015Q216($0.29)($0.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Biopharmx (NYSEAMERICAN:BPMX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Biopharmx (NYSEAMERICAN:BPMX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biopharmx (NYSEAMERICAN BPMX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Biopharmx (NYSEAMERICAN:BPMX)

Biopharmx (NYSEAMERICAN BPMX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/24/2017Stephen MorlockDirectorBuy330,000$0.15$49,500.00View SEC Filing  
11/9/2017Vivo Capital Viii, LlcMajor ShareholderSell296,394$0.20$59,278.80View SEC Filing  
8/1/2017Franklin Resources IncMajor ShareholderBuy250,000$0.34$85,000.00View SEC Filing  
4/28/2017Vivo Capital Fund Viii, L.P.Major ShareholderBuy1,282,052$0.78$1,000,000.56View SEC Filing  
11/28/2016Stephen MorlockDirectorBuy428,571$0.35$149,999.85View SEC Filing  
8/15/2016Franklin Resources IncMajor ShareholderBuy484,615$0.65$314,999.75View SEC Filing  
3/29/2016Franklin Resources IncMajor ShareholderBuy540,000$1.20$648,000.00View SEC Filing  
1/14/2016Stephen MorlockDirectorBuy12,000$1.52$18,240.00View SEC Filing  
1/12/2016Stephen MorlockDirectorBuy6,000$1.53$9,180.00View SEC Filing  
1/7/2016Stephen MorlockDirectorBuy5,000$1.47$7,350.00View SEC Filing  
10/15/2015Stephen MorlockDirectorBuy5,000$1.24$6,200.00View SEC Filing  
10/9/2015Stephen MorlockDirectorBuy3,000$1.21$3,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biopharmx (NYSEAMERICAN BPMX) News Headlines

Source:

SEC Filings

Biopharmx (NYSEAMERICAN:BPMX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Biopharmx (NYSEAMERICAN BPMX) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.